Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


European Journal of Endocrinology, Vol 134, Issue 5, 591-601
Copyright © 1996 by European Society of Endocrinology
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chevalley, T
Right arrow Articles by Linkhart, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chevalley, T
Right arrow Articles by Linkhart, T.

Articles

Evidence for a role for insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation

T Chevalley, DD Strong, S Mohan, D Baylink, and TA Linkhart

Department of Medicine, Loma Linda University, CA, USA.

Glucocorticoids (GCs) inhibit bone formation in vivo and inhibit osteoblast proliferation and collagen synthesis in vitro. These effects may be mediated by alterations in the insulin-like growth factor (IGF) system. In the present study of normal human osteoblast-like (HOB) cells, we tested the hypothesis that dexamethasone (Dex) inhibits IGF anabolic activity in bone by altering expression of IGF binding proteins (IGFBPs), particularly by decreasing expression of IGFBP-5 and IGFBP-3 (which enhance IGF activity) and increasing expression of IGFBP-4 (which inhibits IGF actions). Dexamethasone treatment caused a dose-dependent inhibition of HOB cell proliferation (69 +/- 4% of control at 10(-8) mol/l Dex) in seven separate experiments. Dexamethasone decreased IGFBP-5 mRNA levels to 20-30% of control (10(-8) and 10(-7) mol/l for 24 h). In six of six HOB preparations, 10(-8) mol/l Dex decreased IGFBP-5 mRNA levels (35 +/- 7% of control) and this effect was time dependent. Dexamethasone also decreased IGFBP-3 mRNA levels (74 +/- 9% of control in three HOB preparations). Dexamethasone decreased secretion of 29-31-kD IGFBP-5 and 38-42-kD IGFBP-3 proteins, determined by Western ligand blot and IGFBP-5 immunoblot, and induced a dose-dependent decrease in IGFBP-3 and IGFBP-5 secretion determined by specific radioimmunoassays. The effects of Dex on IGFBP-4 mRNA and on secretion of 25-kD IGFBP-4 levels were inconsistent between different cell preparations. Results suggest that GC inhibition of IGFBP-5 and IGFBP-3 production could decrease IGF activities and contribute to GC inhibition of bone formation.


This article has been cited by other articles:


Home page
J. Cell Sci.Home page
J. E. Phillips, C. A. Gersbach, A. M. Wojtowicz, and A. J. Garcia
Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation
J. Cell Sci., February 1, 2006; 119(3): 581 - 591.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. A. Luppen, N. Leclerc, T. Noh, A. Barski, A. Khokhar, A. L. Boskey, E. Smith, and B. Frenkel
Brief Bone Morphogenetic Protein 2 Treatment of Glucocorticoid-inhibited MC3T3-E1 Osteoblasts Rescues Commitment-associated Cell Cycle and Mineralization without Alteration of Runx2
J. Biol. Chem., November 7, 2003; 278(45): 44995 - 45003.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. M. Ball, D. L. Gillen, D. Sherrard, N. S. Weiss, S. S. Emerson, S. L. Seliger, B. R. Kestenbaum, and C. Stehman-Breen
Risk of Hip Fracture Among Dialysis and Renal Transplant Recipients
JAMA, December 18, 2002; 288(23): 3014 - 3018.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. G. Amaar, G. R. Thompson, T. A. Linkhart, S.-T. Chen, D. J. Baylink, and S. Mohan
Insulin-like Growth Factor-binding Protein 5 (IGFBP-5) Interacts with a Four and a Half LIM Protein 2 (FHL2)
J. Biol. Chem., March 29, 2002; 277(14): 12053 - 12060.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L.-C. C. Yeh and J. C. Lee
Identification of an Osteogenic Protein-1 (Bone Morphogenetic Protein-7)-Responsive Element in the Promoter of the Rat Insulin-Like Growth Factor-Binding Protein-5 Gene
Endocrinology, September 1, 2000; 141(9): 3278 - 3286.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. E. Favoni and A. De Cupis
The Role of Polypeptide Growth Factors in Human Carcinomas: New Targets for a Novel Pharmacological Approach
Pharmacol. Rev., June 1, 2000; 52(2): 179 - 206.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. F. Evans, J. K. Yeh, and J. F. Aloia
Osteoblast-like cells of the hypophysectomized rat: a model of aberrant osteoblast development
Am J Physiol Endocrinol Metab, May 1, 2000; 278(5): E832 - E838.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. Struijs, A. Smals, S. A. de Witte, W. H. L. Hackeng, and H. Mulder
Acute effects of etidronate on glucocorticoid-induced bone degradation
Rheumatology, May 1, 2000; 39(5): 523 - 529.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Boonyaratanakornkit, D. D. Strong, S. Mohan, D. J. Baylink, C. A. Beck, and T. A. Linkhart
Progesterone Stimulation of Human Insulin-like Growth Factor-binding Protein-5 Gene Transcription in Human Osteoblasts Is Mediated by a CACCC Sequence in the Proximal Promoter
J. Biol. Chem., September 10, 1999; 274(37): 26431 - 26438.
[Abstract] [Full Text] [PDF]


Home page
J Intensive Care MedHome page
I. R. Reid
Glucocorticoid Osteoporosis: Reid IR Glucocorticoid osteoporosis J Intensive Care Med 1999, 14231-242
J Intensive Care Med, September 1, 1999; 14(5): 231 - 242.
[PDF]


Home page
Clin. Chem.Home page
P. J. Russell, S. Bennett, and P. Stricker
Growth factor involvement in progression of prostate cancer
Clin. Chem., April 1, 1998; 44(4): 705 - 723.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 European Society of Endocrinology.